BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals today announced that it has initiated IND-enabling pre-clinical toxicology studies for three of its DNA plasmid-based product candidates. The candidates include vaccines for human papilloma virus for the treatment of cervical cancer (VGX-3100) and avian influenza (VGX-3400), and a therapeutic based on human growth hormone releasing hormone (VGX-3200) for cancer related cachexia. VGX is conducting the studies in combination with its patented CELLECTRATM electroporation device and the studies will provide pre-clinical safety data for both the product candidates as well as the device in a GLP environment.
